1H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of…
Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences…
Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue1 IBSRELA achieved $274 million in revenue…
- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy…
New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx’s TAMP Therapy Platform…
– Preferential MOP agonists such as oxycodone are often required for effective management of moderate to severe pain but come…
TORONTO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:MDXXF), a biotechnology…
CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of…
TAIPEI, Taiwan, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Illumina Taiwan Biotechnology Co., Ltd., and Precision Medicine Asia, Limited (PREMIA), a…
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated…